Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 10, Issue 4, 2014, Pages 368-375

  Chan, Arlene ^a   Shannon, Catherine ^d   de Boer, Richard ^e   Baron Hay, Sally ^f   Redfern, Andrew ^b   Bauwens, Astrid ^a   Craft, Paul ^g   Webb, Suzanne ^c   Townsend, Amanda ^h   Kotasek, Dusan ⁱ  

^a CURTIN UNIVERSITY   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c ST JOHN OF GOD HOSPITAL   (Australia)

^d MATER HOSPITAL   (Australia)

^e Epworth Freemasons Hospital   (Australia)

^f Royal NorthShore Hospital   (Australia)

^g CANBERRA HOSPITAL   (Australia)

^h QUEEN ELIZABETH HOSPITAL   (Australia)

ⁱ Adelaide Cancer Centre   (Australia)

Author keywords

HER2 positive breast cancer; Lapatinib capecitabine; Post trastuzumab

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; NAVELBINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; VINBLASTINE;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE PAIN; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH ACNE; STOMATITIS; VOMITING; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MORTALITY; NEOPLASM METASTASIS; PROTO ONCOGENE; RADIOGRAPHY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; VINBLASTINE;

EID: 84909582956     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12292     Document Type: Article

References (27)

1. Slamon D, Leyland-Jones B, Shak S etal. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
2. Marty M, Cognetti F, Maraninchi D etal. Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
3. Burstein H, Kuter I, Campos S etal. Clinical activity of trastuzumab and vinorelbine in women with Her2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-2730.
4. Cameron D, Casey M, Press M etal. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112 (3): 533-543.
5. Nahta R etal. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007; 6.
6. Konecny GE, Pegram MD, Venkatesan N etal. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
7. Krop I, Lorusso P, Miller K etal. A phase II study of Trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012; 30: 3234-3241.
8. Verma S, Miles D, Gianni L etal. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791.
9. Baselga J, Gelmon K, Verma S etal. Phase II trial of pertuzumab and Trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28: 1138-1144.
10. Martin M, Bonneterre J, Geyer C etal. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer 2013; 49 (18): 3763-3772.
11. Chan A, Martin M, Untch M etal. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 2006; 95 (7): 788-793.
12. Chan A. A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol 2007; 18 (7): 1152-1158.
13. Chew HK, Somlo G, Mack P etal. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol 2012; 23 (4): 1023-1029.
14. Brain E, Isambert N, Dalenc F etal. Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. Br J Cancer 2012; 106: 673-677.
15. Saip P, Eralp Y, Sen F etal. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial. Breast 2013; 22 (5): 628-633.
16. Burstein H, Keshaviah A, Baron A etal. Trastuzumab plus vinorelbine or taxane chemotherapy for Her2-overexpressing metastatic breast cancer: the Trastuzumab and vinorelbine or taxane study. Cancer 2007; 110: 965-972.
17. Andersson M, Lidbrink E, Bjerre K etal. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011; 29: 264-271.
18. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E. Gefitinib in patients with brain metastases from non-small cell lung cancer: a prospective trial. Ann Oncol 2004; 15: 1042-1047.
19. Gril B, Palmieri D, Bronder J etal. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008; 100: 1092-1103.
20. Lin N, Dieras V, Paul D etal. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15 (4): 1452-1459.
21. Janni W, Sarosiek T, Karaszewska B etal. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat 2014; 143: 493-505.
22. Giordano S, Buzdar A, Smith T etal. Is breast cancer survival improving? Cancer 2004; 100: 44-52.
23. Dafni U, Grimani I, Xyrafas A, Eleftheraki A, Fountzilas G. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010; 119: 621-631.
24. Chia S, Speers C, D'Yachkova Y etal. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110: 973-979.
25. Hayden E. India spurns cancer patents. Nature 2013; 500: 266.
26. Wagner R. Kantar Health Cancer Treatment in China. 2011 [Cited July 2011.] Available from URL: http://www.kantarhealth.com/docs/ebooks/pharmavoice-cancer-treatment-china-11.pdf?sfvrsn=14
27. Mohanti B, Mukhopadhyay A, Das S, Sharma K, Dash S Estimating the economic burden of cancer at a tertiary pubic hospital: a study at the All India Institute of Medical Sciences. 2011 [Cited July 2011.] Available from URL: www.isid.ac.in/~pu/dispapers/dp11-09.pdf.